ANI Pharmaceuticals (ANIP) Generics and Other — Contingent consideration fair value adjustment

Screener

Other segment segments

Rare Disease and Brands

$0—

Similar metrics at other companies

BROContingent consideration fair value adjustment

$5M+225%

INSMContingent consideration fair value adjustment

-$46.96M-357%

RNGRReportable Segment — Adjustment to contingent consideration

$400K—

INSMReportable Segment — Change in fair value of contingent consideration

-$99.76M-269%

SCSCIntelisys & Advisory — Change in fair value of contingent consideration

$30K-96.3%

WTMHG Global — Change in fair value of contingent consideration

$0—

Other financials

Income statement

See full

Revenue$266.0M+25.9%

Gross profit$165.9M+21.3%

Operating income$40.5M+191%

Net income$24.7M+189%

EPS (diluted)$1.05+192%

Balance sheet

See full

Cash & equivalents$360.2M+65.4%

Total debt$301.5M-4.2%

Total equity$597.2M+36.7%

Total assets$1.5B+11.3%

Cash flow

See full

Operating cash flow$56.7M-25.3%

CapEx$3.1M-23.9%

Free cash flow$53.6M-25.3%

Valuation

See full

Market cap$1.88B+25.6%

Enterprise value$1.82B+14.3%

P/E17.3×—

P/S1.9×-0.1×

Profitability

See full

Gross margin60.4%-0.7pp

Operating margin15.4%—

Net margin11.1%+10.0pp

FCF margin17.7%+0.9pp

Returns & leverage

See full

Return on equity21%+19.1pp

Debt / equity0.5×-0.2×

Current ratio2.9×+0.4×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed: Aug 7, 2026, 7:01 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001023024-26-000069

(in thousands)	Generics and Other	Rare Disease and Brands	Corporate and Unallocated	Total
Research and Development expense	11,186	3,561	—	14,747
Selling, general, and administrative expense	1,578	60,719	29,364	91,661
Depreciation and amortization	—	—	19,640	19,640
Contingent consideration fair value adjustment	—	—	(622)	(622)
Operating Income (Loss)	$36,494	$52,348	$(48,382)	$40,460
Unrealized gain on investment in equity securities	—	—	$741	$741
Interest expense, net	—	—	(3,636)	(3,636)
Other expense, net	—	—	(468)	(468)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is ANI Pharmaceuticals's generics and other — contingent consideration fair value adjustment?: ANI Pharmaceuticals (ANIP) reported generics and other — contingent consideration fair value adjustment of $0 in Q2 2026.
What does generics and other — contingent consideration fair value adjustment mean?: Reflects changes in the estimated fair value of liabilities related to earn-outs or future payments for acquisitions within the generics segment. Fluctuations in this metric indicate changes in management's expectations regarding the future performance of acquired assets or businesses.